Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.
Saved in:
| Title: | Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. |
|---|---|
| Authors: | Qin S; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Fan L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Liang J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Gale R; Department of Medicine, Imperial College London, Centre for Haematology, Division of Experimental Medicine, London, UK., Miao Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wang R; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Yang H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Xia Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wu J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Zhu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Wang L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Xu W; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China., Li J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China. |
| Source: | Hematological oncology [Hematol Oncol] 2018 Oct; Vol. 36 (4), pp. 656-662. Date of Electronic Publication: 2018 Jun 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 29901220 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Fan+L%22">Fan L</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Liang+J%22">Liang J</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Gale+R%22">Gale R</searchLink>; Department of Medicine, Imperial College London, Centre for Haematology, Division of Experimental Medicine, London, UK.<br /><searchLink fieldCode="AU" term="%22Miao+Y%22">Miao Y</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wu+Y%22">Wu Y</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wang+R%22">Wang R</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Xia+Y%22">Xia Y</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wu+J%22">Wu J</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Zhu+H%22">Zhu H</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Xu+W%22">Xu W</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228307268%22">Hematological oncology</searchLink> [Hematol Oncol] 2018 Oct; Vol. 36 (4), pp. 656-662. <i>Date of Electronic Publication: </i>2018 Jun 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8307268 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1099-1069 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2202780232%22">02780232 </searchLink><i>NLM ISO Abbreviation: </i>Hematol Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29901220 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/hon.2520 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 656 Titles: – TitleFull: Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Qin S – PersonEntity: Name: NameFull: Fan L – PersonEntity: Name: NameFull: Liang J – PersonEntity: Name: NameFull: Gale R – PersonEntity: Name: NameFull: Miao Y – PersonEntity: Name: NameFull: Wu Y – PersonEntity: Name: NameFull: Wang R – PersonEntity: Name: NameFull: Yang H – PersonEntity: Name: NameFull: Wu W – PersonEntity: Name: NameFull: Xia Y – PersonEntity: Name: NameFull: Wu J – PersonEntity: Name: NameFull: Zhu H – PersonEntity: Name: NameFull: Wang L – PersonEntity: Name: NameFull: Xu W – PersonEntity: Name: NameFull: Li J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2018 Oct Type: published Y: 2018 Identifiers: – Type: issn-electronic Value: 1099-1069 Numbering: – Type: volume Value: 36 – Type: issue Value: 4 Titles: – TitleFull: Hematological oncology Type: main |
| ResultId | 1 |
